Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 164

Results For "X"

9462 News Found

Biological E gets nod to study Corbevax as a booster dose
News | December 30, 2021

Biological E gets nod to study Corbevax as a booster dose

The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions


Granules receives ANDA approval for amphetamine mixed salts
Drug Approval | December 30, 2021

Granules receives ANDA approval for amphetamine mixed salts

The current annual U.S. market for amphetamine mixed salts, USP 1.25mg, 1.875mg, 2.5mg, 3.125mg, 3.75mg, 5mg, 7.5mg immediate release tablets strengths is approximately US $ 335 million, according to MAT, Oct 2021 IQVIA/IMS Health


Study demonstrates Covaxin safe for kids in the age 2-18 years
News | December 30, 2021

Study demonstrates Covaxin safe for kids in the age 2-18 years

Covaxin has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study. Neutralizing antibodies in children on an average 1.7 times higher than in adults


JB Chemicals and Pharmaceuticals to launch molnupiravir next month
Drug Approval | December 29, 2021

JB Chemicals and Pharmaceuticals to launch molnupiravir next month

It will be marketed under the brand name Molunamax


Trastuzumab deruxtecan type II variation application validated by EMA
Biotech | December 28, 2021

Trastuzumab deruxtecan type II variation application validated by EMA

Application based on DESTINY-Breast03 results showing Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan reduced risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1)


Sun Pharma receives DCGI approval for Molxvir in India
Drug Approval | December 28, 2021

Sun Pharma receives DCGI approval for Molxvir in India

The product is expected to be available in a week’s time


CDSCO expert committee recommends Emergency Use Authorisation to Covovax and Corbevax
News | December 28, 2021

CDSCO expert committee recommends Emergency Use Authorisation to Covovax and Corbevax

All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.


Expectations and predictions for 2022
Opinion | December 28, 2021

Expectations and predictions for 2022

In India, healthcare has become one of the fastest-growing economic sectors which comprise hospitals, pharma companies, medical equipment and devices, medical tourism, health insurance, clinical trials etc


India’s 1st indigenously developed protein sub-unit Covid-19 vaccine Corbevax gets nod
Drug Approval | December 28, 2021

India’s 1st indigenously developed protein sub-unit Covid-19 vaccine Corbevax gets nod

It plans to deliver over 300 million doses to the Indian government


Covaxin receives approval for Emergency Use in Children 12-18 years
Drug Approval | December 27, 2021

Covaxin receives approval for Emergency Use in Children 12-18 years

Covaxin is formulated uniquely such that the same dosage can be administered to adults and children